Cue Biopharma

Mobilizing the Patient’s Immune System to Treat Serious Diseases

DESIGNED FOR SELECTIVITY

Our engineered biologics are designed to mimic nature’s signals to selectively expand and activate specific immune cells and restore immune balance.

Virtual R&D Day Event
to Discuss CUE-401, the Company's Lead Asset for
the Treatment of Autoimmune and Inflammatory Diseases
Tuesday, April 7, 2026 | 10:00 AM EDT
Click Here to Register & Attend

CURRENT NEWS

Cue Biopharma in the news

View all news
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
Read press release
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Read press release
Virtual Investor Event May 2025
Access Replay Download Presentation
View all news